ArticleJournal of the Endocrine Society2022

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.

Noriyuki Namba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.